Antibody drug conjugates in older patients: State of the art
Authors:
- Layal RachedLRLayal Rached
- Arthur GeraudAGArthur Geraud
- Maxime FrelautMFMaxime Frelaut
- Zoe AP ThomasZTZoe AP Thomas
- Vincent GoldschmidtVGVincent Goldschmidt
- Geoffroy Beraud-ChauletGBGeoffroy Beraud-Chaulet
- Celine Nagera-LazaroviciCNCeline Nagera-Lazarovici
- Francois-Xavier DanlosFDFrancois-Xavier Danlos
- Clemence HenonCHClemence Henon
- Claudia ParisiCPClaudia Parisi
- Anas GazzahAGAnas Gazzah
- Rastilav BahledaRBRastilav Bahleda
- 24 November 2023
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 193, 104212
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 studyThe Lancet Oncology, 2017
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2016
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 TrialJournal of Clinical Oncology, 2016
- Antibody‐Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer TherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderBlood, 2015
- Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariatesCancer Chemotherapy and Pharmacology, 2014
- Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)Journal of Clinical Oncology, 2013
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD studyBlood, 2012
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studyThe Lancet, 2012